Taiho Oncology’s Futibatinib (TAS-120) Receives the US FDA’s Breakthrough Therapy Designation for Advanced Cholangiocarcinoma

April 5, 2021 Auto Bot Advanced, Breakthrough Therapy Designation, FDA, receives, regulatory, Treatment 0

Shots:

  • The designation is based on efficacy & safety results from the P-II FOENIX-CCA2 study involves assessing futibatinib (TAS-120) in patients with advanced cholangiocarcinoma. The findings will be presented at AACR 2021
  • The preliminary clinical evidence showed improvement on at least one clinical EPs over available therapy
  • Futibatinib (TAS-120, PO) is a covalently-binding FGFR inhibitor for the treatment of patients with previously treated LA/m-cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

The post Taiho Oncology’s Futibatinib (TAS-120) Receives the US FDA’s Breakthrough Therapy Designation for Advanced Cholangiocarcinoma first appeared on PharmaShots.